Skip to main content
OpenTrials
Completed

NCT Number: NCT01153581

Sex Hormones and Orthostatic Tolerance

This study is designed to determine the causes of "orthostatic intolerance" which occurs more commonly in women than in men. Orthostatic tolerance is the ability to remain standing up right for long periods of time, or to avoid dizziness when moving to standing from a seated or lying position.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–34 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

John B. Pierce Laboratory

New Haven, Connecticut, 06519, United States

About this study

In this study we are interested in determining the impact of female reproductive hormones (estrogen and progesterone) on orthostatic tolerance (described above) so we administer these hormones to participants. We also test participants' orthostatic tolerance in our laboratory and use this information to place subjects into groups.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, English-speaking non-smoking women age 18- 34 with regular menses

Exclusion criteria

  • Gynecologic:
  • current or past estrogen-dependent neoplasia,
  • unexplained vaginal bleeding,
  • history of uterine fibroids,
  • current pregnancy,
  • known or suspected breast or uterine cancer,
  • partial or complete hysterectomy
  • Cardiac:
  • myocardial infarction, ventricle tachycardia or fibrillation,
  • angina,
  • valvular disease,
  • congestive heart failure, orthopnea, paroxysmal nocturnal dyspnea,
  • current arrhythmias,
  • prosthetic valves
  • Pulmonary:
  • current cigarette smokers, or pipe or cigar smokers,
  • chronic obstructive pulmonary disease,
  • adult asthma,
  • dyspnea on exertion,
  • current bronchitis, pneumonia, or tuberculosis,
  • lung carcinoma,
  • pulmonary embolus, recent
  • Vascular:
  • claudication or history of peripheral vascular disease,
  • abdominal or thoracic aortic aneurysm, or repair of same,
  • cerebral aneurysm, vascular malformations,
  • hypertension, systolic or diastolic, or strong family history of hypertension
  • Gastrointestinal:
  • GI malignancy,
  • hepatitis, current,
  • splenomegaly from any cause,
  • Cholecystitis,
  • current diverticulosis or diverticulitis, inflammatory bowel disease, ulcerative colitis, Crohn's Disease,
  • previous gastrointestinal surgery
  • Infectious Disease: any intercurrent infection
  • Hematologic/Oncologic:
  • receiving chemotherapy or radiation therapy,
  • any metastatic malignancy,
  • anemia (hematocrit < 35),
  • thrombocytopenia or thrombocytosis,
  • neutropenia,
  • hematologic malignancy,
  • bleeding dyscrasia
  • Neurologic:
  • history of cerebral vascular accident with any neurologic sequels,
  • uncontrolled seizures (e.g. more than 1 seizure/year),
  • transient ischemic attacks,
  • dementia,
  • neurologic conditions producing dyscoordination, peripheral neuropathy, or myopathy,
  • severe migraine headaches
  • Endocrine:
  • diabetes mellitus,
  • any untreated endocrinopathy
  • Renal:
  • chronic renal disease,
  • any history of renal disease or impairment,
  • current urinary tract infection
  • Musculoskeletal:
  • inflammatory arthritis history (e.g., rheumatoid, psoriatic, Reiters),
  • any history of pathologic fractures, including vertebral compression fractures
  • Pharmacologic:
  • any illegal drug use,
  • alcohol use greater than an average of 4 oz/day over 30 days,
  • coumadin or heparin use,
  • current systemic antifungal use

Treatment and study plan

ganirelix acetate

Drug

Ganirelix acetate: .25 ml/day by subcutaneous injection

Other names: Antagon

17β-Oestradiol

Drug

17 beta estradiol: 0.2 mg/day (patches)

Other names: 17 beta estradiol, estradiol

Progesterone

Drug

progesterone, 200 mg day-1 oral

Other names: P4, Prometrium

Primary outcomes

  1. Orthostatic Tolerance

    Time frame: 2 months

    We used a measure called cumulative stress index to determine orthostatic tolerance, which is the amount of time at a level of negative pressure each subject can maintain before feeling as if she is going to pass out. This is calculated by multiplying the pressure in mm Hg by the time in min.

  2. Baroreceptor Function

    Time frame: 2 months

    This is a measure of how the body responds to changes in pressure induced by changes in position such as sitting, lying standing. The pressure changes are induced by gravity. The measurement described below to assess baroreceptor function is units of change in forearm vascular resistance for a given change in lower body negative pressure. This allows us to determine how good the body is at sending signals to the periphery to respond to postural changes.

    Baroreflex sensitivity is defined as the change in interbeat interval (IBI) in milliseconds per unit change in BP. For example, when the BP rises by 10 mmHg and IBI increases by 100 ms, BRS would be 100/10 = 10 ms/mmHg.

  3. Skin Microvascular Responses

    Time frame: 2 months

    Changes in blood flow in the small vessel in the skin are measured in response to sequential heat and drug stimulation. It is measured in volts, and then corrected for a maximum level and expressed as "% max." This is measured with a Laser Doppler probes, which measures volts.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Important dates

Study start
2006
Primary completion
2012
Study completion
2013
First posted
Jun 30, 2010
Registry last updated
Dec 13, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.